4d hails ‘significant step forward’ in research update

MEDICAL research company 4d Pharma has given a second positive research update in three days.

Since floating on AIM last year, shares in the Manchester company have defied a sometimes turbulent stock market to more than double to 435p. The stock rose again in early trading to 464.5p, up nearly 7%.

4d’s latest news focuses on the MicroRx Platform which is developing new live bacteria to create bioterapeutics to treat inflammatory and auto-immune diseases.

It began working on MicroRX  in May 2014, and the early results have been very promising.

The company said: “The board of 4D is pleased to report that the company’s MicroRx platform has identified a number of bacteria that have demonstrated therapeutically relevant effects in pre-clinical models of rheumatoid arthritis, allergic asthma and severe, steroid resistant asthma.”

Chairman David Norwood, added: “Our library of bacteria is extensive, putting 4D in a world leading position in being able to continue to mine for therapeutics that could have a curative effect in a variety of important diseases with significant unmet needs.

“The ability of the MicroRx platform to rationally select bacteria from this library and demonstrate therapeutically relevant effects in models of disease in a matter of months is extraordinary.

“This is not only a significant step forward for 4D, but also the area of live biotherapeutics in general, demonstrating that the microbiome potentially has a significant role to play in disease and its treatment.”

Close